Analyst Consensus ?
ConsensusBuy34 ratings
Bullish2573.5%
Neutral926.5%
Bearish00.0%
Labcorp Holdings Inc. · LH · FY2025 Q1 · Calendar Q2 2025
Labcorp raises EPS outlook as diagnostics growth and savings build
The current call supports a constructive but conditional growth thesis: demand, new diagnostic offerings, acquisitions, and LaunchPad savings are supporting growth and margin expansion, while tariffs, regulation, pricing, and integration remain material counterweights.
Reported Before market openNYSEHealthcare
$25.79B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $3.74
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $3.40B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+4.7%
Event window
SPY move
+0.6%
Same window
Abnormal move
+4.1%
Stock minus SPY
Volume
2.4×
Versus trailing sessions
Subsequent drift
+2.7%
Up to 20 sessions
LHSPY benchmark
Ask FN2 about LH FY2025 Q1
Transcript, numbers and history already loaded
What drove LH's +4.7% move after FY2025 Q1 earnings?What changed in LH's guidance and outlook in FY2025 Q1?Give me the bull and bear case for LH after FY2025 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, management moved from maintained guidance to a higher EPS guidance midpoint, while emphasizing a 5% revenue increase, diagnostic volume recovery, new test launches, and additional BioReference-related assets. The main uncertainties remain tariffs, PAMA and other regulation, weather normalization, pricing pressure, and integration.
Guidance delta
Management raised the midpoint of full-year EPS guidance by $0.05 while reaffirming the revenue and free-cash-flow outlook.
Key takeaways
- Revenue grew 5% year over year, with diagnostics up 6% and BLS up 3%.
- Management cited organic volume, price mix, new tests, Invitae integration, and LaunchPad savings as growth and margin drivers.
- The company highlighted Plasma Complete, Alzheimer’s blood testing, digital billing tools, and further oncology and regional-lab expansion.
Management priorities
- Expand tests in oncology, neurology, women’s health, and autoimmune disease.
- Scale AI-enabled digital tools, including Diagnostic Assistant and eClaim Assist.
- Continue acquisitions, LaunchPad cost actions, and monitoring of tariff and regulatory developments.
Follow LH with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$317.95Current
$240Low
$314.32Average
$380High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 17, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Buy | Buy | Maintain | Sep 21, 2026 |
| UBS | Buy | Buy | Maintain | Sep 11, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Sep 11, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Aug 4, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Aug 3, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 31, 2026 |
| Baird | Outperform | Outperform | Maintain | Jul 13, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 13, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Apr 8, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Oct 17, 2025 |
| Citigroup | Buy | Neutral | Upgrade | Mar 4, 2025 |
| Jefferies | Buy | Buy | Maintain | Feb 6, 2025 |
| HSBC | Buy | Hold | Upgrade | Oct 30, 2024 |
| Deutsche Bank | Hold | Hold | Maintain | Aug 2, 2024 |
| Argus Research | Buy | Hold | Upgrade | Mar 25, 2024 |
| Wells Fargo | Overweight | Overweight | Maintain | Aug 14, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 2, 2023 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Jul 13, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | May 21, 2020 |
| Keybanc | Overweight | Overweight | Maintain | Mar 30, 2020 |
| Bank of America | Neutral | Underperform | Upgrade | Jul 16, 2019 |
| Canaccord Genuity | Hold | Hold | Maintain | May 2, 2019 |
| Goldman Sachs | Buy | Conviction Buy | Downgrade | Nov 30, 2018 |
| Argus | Hold | Buy | Downgrade | Oct 30, 2018 |
| JMP Securities | Outperform | Market Outperform | Maintain | Mar 27, 2015 |
| Maxim Group | Buy | Buy | Maintain | Mar 24, 2015 |
| PiperJaffray | Overweight | Neutral | Upgrade | Feb 23, 2015 |
| Raymond James | Outperform | Underperform | Upgrade | Jan 2, 2015 |
| FBR Capital | Market Perform | Market Perform | Maintain | Oct 28, 2014 |
| William Blair | Outperform | Market Perform | Upgrade | Jul 17, 2014 |
| Cantor Fitzgerald | Buy | Buy | Maintain | May 9, 2014 |
| ISI Group | Neutral | Neutral | Maintain | Nov 19, 2013 |
| Craig-Hallum | Buy | Buy | Maintain | Aug 28, 2013 |
| Oppenheimer | Perform | Perform | Maintain | Jan 28, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $317.95. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Truist Financial | David MacDonald | $365 | $320.71 | +14.8% | Sep 21, 2026 |
| UBS | Kevin Caliendo | $380 | $307.42 | +19.5% | Sep 11, 2026 |
| Barclays | Analyst unavailable | $330 | $306.96 | +3.8% | Sep 11, 2026 |
| Mizuho Securities | Ann Hynes | $355 | $319.17 | +11.7% | Aug 10, 2026 |
| Morgan Stanley | Analyst unavailable | $338 | $308.64 | +6.3% | Jul 31, 2026 |
| Deutsche Bank | Analyst unavailable | $306 | $308.7 | -3.8% | Jul 31, 2026 |
| Robert W. Baird | Analyst unavailable | $352 | $315.53 | +10.7% | Jul 31, 2026 |
| Barclays | Analyst unavailable | $320 | $315.82 | +0.6% | Jul 30, 2026 |
| Robert W. Baird | Eric Coldwell | $334 | $255.97 | +5.0% | May 1, 2026 |
| Evercore ISI | Analyst unavailable | $300 | $274.72 | -5.6% | Apr 8, 2026 |
| Piper Sandler | David Westenberg | $300 | $285.3 | -5.6% | Feb 24, 2026 |
| Robert W. Baird | Analyst unavailable | $326 | $276.67 | +2.5% | Feb 18, 2026 |
| Robert W. Baird | Analyst unavailable | $313 | $259.18 | -1.6% | Jan 14, 2026 |
| UBS | Kevin Caliendo | $320 | $253.74 | +0.6% | Oct 29, 2025 |
| Robert W. Baird | Analyst unavailable | $304 | $259.69 | -4.4% | Oct 29, 2025 |
| Leerink Partners | Michael Cherny | $342 | $261.62 | +7.6% | Oct 28, 2025 |
| UBS | Analyst unavailable | $325 | $285.93 | +2.2% | Oct 17, 2025 |
| Mizuho Securities | Ann Hynes | $320 | $283.71 | +0.6% | Oct 17, 2025 |
| Truist Financial | Analyst unavailable | $320 | $278.42 | +0.6% | Oct 14, 2025 |
| Evercore ISI | Analyst unavailable | $305 | $279.44 | -4.1% | Oct 3, 2025 |
| Barclays | Analyst unavailable | $290 | $279.06 | -8.8% | Oct 2, 2025 |
| Robert W. Baird | Analyst unavailable | $311 | $276.11 | -2.2% | Aug 25, 2025 |
| UBS | Kevin Caliendo | $305 | $264.96 | -4.1% | Jul 25, 2025 |
| Barclays | Analyst unavailable | $275 | $258.7 | -13.5% | Jun 25, 2025 |
| Barclays | Luke Sergott | $271 | $247.86 | -14.8% | Feb 3, 2025 |
| Evercore ISI | Elizabeth Anderson | $240 | $224.72 | -24.5% | Sep 24, 2024 |
| Jefferies | Brian Tanquilut | $265 | $222.22 | -16.7% | Sep 23, 2024 |
| Bank of America Securities | Michael Ryskin | $260 | $236 | -18.2% | Aug 5, 2024 |
| Robert W. Baird | Eric Coldwell | $277 | $235.67 | -12.9% | Aug 2, 2024 |
| Argus Research | David Toung | $250 | $212.5 | -21.4% | Mar 25, 2024 |
| Morgan Stanley | Analyst unavailable | $303 | $241.42 | -4.7% | Jan 6, 2023 |
| Credit Suisse | Analyst unavailable | $305 | $238 | -4.1% | Nov 23, 2022 |
| Mizuho Securities | Analyst unavailable | $296 | $254.72 | -6.9% | Jul 29, 2022 |
| Deutsche Bank | Analyst unavailable | $265 | $245.45 | -16.7% | May 3, 2022 |
| Credit Suisse | Analyst unavailable | $312 | $240.28 | -1.9% | May 2, 2022 |
| Wells Fargo | Analyst unavailable | $315 | $266.12 | -0.9% | Apr 25, 2022 |
| Bank of America Securities | Derik de Bruin | $370 | $276.26 | +16.4% | Feb 11, 2022 |
| Deutsche Bank | Pito Chickering | $294 | $270.08 | -7.5% | Jan 28, 2022 |
| Truist Financial | David S Macdonald | $350 | $296.15 | +10.1% | Jul 30, 2021 |
| Argus Research | Jasper Hellweg | $295 | $269.61 | -7.2% | May 20, 2021 |
Track every rating change on LH the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationLabcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
Historical context
All LH earningsLatest beats and misses
Who reports nextBeat on EPS
Get the LH recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-04-15T00:03:42.498162+00:00
- Polygon adjusted daily market bars · 2026-10-17T10:40:42.615682+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-17T10:40:42.612131+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-17. For educational purposes only; not investment advice.